Description: Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains. The company was founded in 2011 and is based in Cambridge, Massachusetts with an additional location in Gosselies, Belgium.
Home Page: www.iteostherapeutics.com
ITOS Technical Analysis
321 Arsenal Street
Cambridge,
MA
02472-5710
United States
Phone:
339 217 0161
Officers
| Name | Title |
|---|---|
| Dr. Michel Detheux Ph.D. | Pres, CEO & Director |
| Mr. Matthew A. Call M.B.A. | Chief Operating Officer |
| Dr. Joanne Jenkins-Lager M.D. | Chief Medical Officer |
| Mr. Matthew Gall | Chief Financial Officer |
| Dr. Yvonne McGrath Ph.D. | Chief Scientific Officer |
| Mr. Ryan Baker | Head of Investor Relations |
| Mr. Phillipe Brantegem | Vice-Pres of HR |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 12.5628 |
|---|---|
| Trailing PE: | 2.7686 |
| Price-to-Book MRQ: | 1.187 |
| Price-to-Sales TTM: | 1.6815 |
| IPO Date: | 2020-07-24 |
| Fiscal Year End: | December |
| Full Time Employees: | 94 |